S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in
NASDAQ:KDNY

Chinook Therapeutics Stock Forecast, Price & News

$17.36
+0.13 (+0.75 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.62
Now: $17.36
$17.64
50-Day Range
$14.17
MA: $15.48
$17.23
52-Week Range
$9.35
Now: $17.36
$21.68
Volume104,077 shs
Average Volume101,444 shs
Market Capitalization$731.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.26
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Chinook Therapeutics logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KDNY
CUSIPN/A
CIKN/A
Phone510-848-4400
Employees43
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.26 million
Book Value$4.07 per share

Profitability

Net Income$-82,370,000.00
Net Margins-215.80%

Miscellaneous

Market Cap$731.86 million
Next Earnings Date3/8/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

384th out of 1,969 stocks

Pharmaceutical Preparations Industry

198th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$17.36
+0.13 (+0.75 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KDNY News and Ratings via Email

Sign-up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chinook Therapeutics (NASDAQ:KDNY) Frequently Asked Questions

Is Chinook Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chinook Therapeutics stock.
View analyst ratings for Chinook Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Chinook Therapeutics?

Wall Street analysts have given Chinook Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chinook Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chinook Therapeutics' next earnings date?

Chinook Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Chinook Therapeutics
.

What price target have analysts set for KDNY?

7 brokerages have issued 12 month price objectives for Chinook Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they expect Chinook Therapeutics' share price to reach $30.33 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price.
View analysts' price targets for Chinook Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Chinook Therapeutics' key executives?

Chinook Therapeutics' management team includes the following people:
  • Mr. Eric L. Dobmeier, Pres, CEO & Director (Age 52)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 61)
  • Ms. Noopur Batsha Liffick, VP of Investor Relations & Corp. Communications
  • Mr. Kirk D. Schumacher J.D., Sr. VP & Gen. Counsel
  • Ms. Jodi Jamieson, VP of HR
  • Mr. Tom Frohlich, Chief Bus. Officer
  • Mr. Alan Glicklich M.D., Chief Medical Officer
  • Mr. Andrew James King D.V.M., Ph.D., Head of Renal Discovery & Translational Medicine
  • Ms. Renata Oballa Ph.D., VP of Chemistry & Vancouver Site Head

Who are some of Chinook Therapeutics' key competitors?

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent Inc. (RX.V) (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

Who are Chinook Therapeutics' major shareholders?

Chinook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Samsara BioCapital LLC (7.52%), BlackRock Inc. (3.34%), Orbimed Advisors LLC (2.97%), Baillie Gifford & Co. (2.00%), Renaissance Technologies LLC (1.98%) and Baker BROS. Advisors LP (1.78%).
View institutional ownership trends for Chinook Therapeutics
.

Which major investors are selling Chinook Therapeutics stock?

KDNY stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., and Panagora Asset Management Inc..
View insider buying and selling activity for Chinook Therapeutics
or view top insider-selling stocks.

Which major investors are buying Chinook Therapeutics stock?

KDNY stock was bought by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, BlackRock Inc., Orbimed Advisors LLC, Renaissance Technologies LLC, Baker BROS. Advisors LP, Monashee Investment Management LLC, Northern Trust Corp, and JPMorgan Chase & Co..
View insider buying and selling activity for Chinook Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Chinook Therapeutics?

Shares of KDNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $17.36.

How much money does Chinook Therapeutics make?

Chinook Therapeutics has a market capitalization of $731.86 million and generates $17.26 million in revenue each year. The company earns $-82,370,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

Chinook Therapeutics employs 43 workers across the globe.

What is Chinook Therapeutics' official website?

The official website for Chinook Therapeutics is chinooktx.com.

Where are Chinook Therapeutics' headquarters?

Chinook Therapeutics is headquartered at 740 HEINZ AVENUE, BERKELEY CA, 94710.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The company can be reached via phone at 510-848-4400 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.